文献速递心脑血管急症

超24小时时间窗卒中的血管内治疗:系统综述与Meta分析

Endovascular Therapy for Stroke Presenting Beyond 24 Hours: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Netw Open · 2023-05-01
一句话结论超24小时时间窗急性缺血性卒中行血管内治疗,90天功能独立32.0%、TICI 2b-3开通81.9%、sICH 6.8%、90天死亡27.2%,作者认为可能安全且与结局改善相关,但需RCT与前瞻性对照研究确定获益人群。

该系统综述与Meta分析检索Web of Science、Embase、Scopus和PubMed自建库至2022年12月13日的英文文献,最终纳入2018至2023年间发表的7项研究、共569例超24小时时间窗急性缺血性卒中接受血管内治疗的患者,采用随机效应模型合并频率与均值。患者基线NIHSS均值13.6(95%CI 11.9-15.5)、ASPECTS均值7.9(95%CI 7.2-8.7),最后已知正常和/或发病至穿刺时间均值46.2小时(95%CI 32.4-65.9小时)。主要结局90天mRS 0-2为32.0%(95%CI 24.7%-40.2%),TICI 2b-3为81.9%(95%CI 78.5%-84.9%),TICI 3为45.3%(95%CI 36.6%-54.4%),sICH 6.8%(95%CI 4.3%-10.7%),90天死亡27.2%(95%CI 22.9%-31.9%),ENI 36.9%(95%CI 26.4%-48.9%),END 14.3%(95%CI 7.1%-26.7%)。作者认为这些结果提示超晚时间窗血管内治疗可能安全且与结局改善相关,但需RCT和前瞻性对照研究确定哪些患者可能获益。

要点

  • 超24小时时间窗AIS血管内治疗:90天mRS 0-2为32.0%(95%CI 24.7%-40.2%),TICI 2b-3为81.9%(95%CI 78.5%-84.9%)。
  • 超24小时时间窗AIS血管内治疗:sICH 6.8%(95%CI 4.3%-10.7%),90天死亡27.2%(95%CI 22.9%-31.9%)。
  • 超24小时时间窗AIS血管内治疗:TICI 3为45.3%(95%CI 36.6%-54.4%),ENI 36.9%(95%CI 26.4%-48.9%),END 14.3%(95%CI 7.1%-26.7%)。
  • 纳入患者基线NIHSS均值13.6(95%CI 11.9-15.5)、ASPECTS均值7.9(95%CI 7.2-8.7),最后已知正常和/或发病至穿刺时间均值46.2小时(95%CI 32.4-65.9小时)。
  • 作者认为超晚时间窗血管内治疗可能安全且与结局改善相关,但需RCT和前瞻性对照研究确定哪些患者可能获益。

适用人群与场景

  • 超24小时时间窗急性缺血性卒中并接受血管内治疗的患者;7项研究共569例,发表于2018至2023年。
  • 检索范围:Web of Science、Embase、Scopus和PubMed自建库至2022年12月13日的英文文献。

研究设计与关键结果

  • 研究类型:系统综述与Meta分析,检索1754项研究后最终纳入7项研究、共569例超24小时时间窗AIS接受血管内治疗的患者,数据采用随机效应模型合并,按PRISMA 2020报告,方案在PROSPERO前瞻性注册。
  • 基线:NIHSS均值13.6(95%CI 11.9-15.5),ASPECTS均值7.9(95%CI 7.2-8.7),最后已知正常和/或发病至穿刺时间均值46.2小时(95%CI 32.4-65.9小时)。
  • 主要结局:90天mRS 0-2(功能独立)为32.0%(95%CI 24.7%-40.2%)。
  • 关键次要结局:TICI 2b-3为81.9%(95%CI 78.5%-84.9%),TICI 3为45.3%(95%CI 36.6%-54.4%),sICH 6.8%(95%CI 4.3%-10.7%),90天死亡27.2%(95%CI 22.9%-31.9%),ENI 36.9%(95%CI 26.4%-48.9%),END 14.3%(95%CI 7.1%-26.7%)。

证据类型、等级与局限

  • 证据类型:系统综述与Meta分析,纳入7项已发表研究(非随机对照试验),按PRISMA 2020报告,方案在PROSPERO前瞻性注册。
  • 作者结论:超晚时间窗AIS的血管内治疗与有利的90天mRS 0-2和TICI 2b-3频率相关,且90天死亡和sICH频率低;这些结果提示血管内治疗可能安全且与结局改善相关,但需RCT和前瞻性对照研究确定哪些患者可能从超晚干预中获益。

对床旁实践的改变

  • 作者认为超24小时时间窗AIS行血管内治疗可能安全且与结局改善相关(90天mRS 0-2为32.0%,TICI 2b-3为81.9%)。
  • 作者建议需RCT和前瞻性对照研究确定哪些患者可能从超晚时间窗干预中获益,本文结果不构成对超24小时时间窗血管内治疗的推荐。

指南或共识出处

  • JAMA Network Open发表的系统综述与Meta分析:Endovascular Therapy for Stroke Presenting Beyond 24 Hours: A Systematic Review and Meta-analysis(2018至2023年纳入研究)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Previous randomized clinical trials (RCTs) have supported the use of endovascular therapy (EVT) in late-window acute ischemic stroke (AIS; 6-24 hours). However, little is known about the use of EVT in very late-window AIS (>24 hours).

OBJECTIVE: To examine outcomes following EVT for very late-window AIS.

DATA SOURCES: A systematic review of the English language literature was conducted using Web of Science, Embase, Scopus, and PubMed to search for articles published from database inception until December 13, 2022.

STUDY SELECTION: This systematic review and meta-analysis included published studies regarding very late-window AIS treated with EVT. Multiple reviewers screened studies, and an extensive manual search of the references of included articles was performed to identify any missed articles. Of the 1754 initially retrieved studies, 7 published between 2018 and 2023 were ultimately included.

DATA EXTRACTION AND SYNTHESIS: Data were extracted independently by multiple authors and evaluated for consensus. Data were pooled using a random-effects model. This study is reported per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guideline, and the protocol was prospectively registered with PROSPERO.

MAIN OUTCOMES AND MEASURES: The primary outcome of interest was functional independence, as assessed with 90-day modified Rankin Scale (mRS) scores (0-2). Secondary outcomes included thrombolysis in cerebral infarction (TICI) scores (2b-3 or 3), symptomatic intracranial hemorrhage (sICH), 90-day mortality, early neurological improvement (ENI), and early neurological deterioration (END). Frequencies and means were pooled with the corresponding 95% CIs.

RESULTS: This review included 7 studies involving a total of 569 patients. The mean baseline National Institutes of Health Stroke Scale score was 13.6 (95% CI, 11.9-15.5), and the mean Alberta Stroke Program Early CT Score was 7.9 (95% CI, 7.2-8.7). The mean time from last known well and/or onset to puncture was 46.2 hours (95% CI, 32.4-65.9 hours). Frequencies for the primary and secondary outcomes were 32.0% (95% CI, 24.7%-40.2%) for functional independence (90-day mRS scores of 0-2) and 81.9% (95% CI, 78.5%-84.9%) for TICI scores of 2b to 3, 45.3% (95% CI, 36.6%-54.4%) for TICI scores of 3, 6.8% (95% CI, 4.3%-10.7%) for sICH, and 27.2% (95% CI, 22.9%-31.9%) for 90-day mortality. In addition, frequencies were 36.9% (95% CI, 26.4%-48.9%) for ENI and 14.3% (95% CI, 7.1%-26.7%) for END.

CONCLUSIONS AND RELEVANCE: In this review, EVT for very late-window AIS was associated with favorable frequencies of 90-day mRS scores of 0 to 2 and TICI scores of 2b to 3 and with low frequencies of 90-day mortality and sICH. These results suggest that EVT may be safe and associated with improved outcomes for very late-window AIS, although RCTs and prospective, comparative studies are needed to determine which patients may benefit from very late intervention.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Kobeissi H, Ghozy S, Adusumilli G, et al. Endovascular Therapy for Stroke Presenting Beyond 24 Hours: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023. PMID: 37140919. doi:10.1001/jamanetworkopen.2023.11768

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。